Laczó Andrea, Bódis József, Bogner Péter, Molnár Krisztián, Vajda Réka, Pónusz-Kovács Dalma, Elmer Diána, Kajos Fanni Luca, Csákvári Tímea, Kívés Zsuzsanna, Boncz Imre
Dél-dunántúli Területi Koordinációs Osztály, Országos Kórházi Főigazgatóság, Pécs, Hungary.
Egészségtudományi Kar, Pécsi Tudományegyetem, Egészségbiztosítási Intézet, Pécs, Hungary.
Magy Onkol. 2022 Oct 5;66(3):195-200. Epub 2022 Sep 7.
The aim of our study is to analyze the participation indicators of screening rounds Nr. 6-10 (2012-2021) of the organized nationwide mammography screening program. Data derived from the nationwide financing database of the Hungarian National Health Insurance Fund Management and covered the period 2012-2021. We analyzed both diagnostic and screening mammography examinations. Between 2012 and 2019 the coverage (screening and diagnostic mammography) varied between 48.1-51.5, which decreased to 31.8% in 2020-2021. Within total coverage, the organized screening rate declined from 30.3-31.2 to 20.0, while the diagnostic mammography rate decreased from 17.7-20.7% to 11.8%. We can conclude that the number of both the diagnostic and screening mammography declined. In order to reduce the mortality of breast cancer, participation rate of mammography screening program should be increased.
我们研究的目的是分析全国有组织的乳腺钼靶筛查计划第6 - 10轮（2012 - 2021年）的参与指标。数据来源于匈牙利国家健康保险基金管理的全国融资数据库，涵盖2012 - 2021年期间。我们分析了诊断性和筛查性乳腺钼靶检查。2012年至2019年期间，覆盖率（筛查性和诊断性乳腺钼靶检查）在48.1% - 51.5%之间变化，2020 - 2021年降至31.8%。在总覆盖率中，有组织的筛查率从30.3% - 31.2%降至20.0%，而诊断性乳腺钼靶检查率从17.7% - 20.7%降至11.8%。我们可以得出结论，诊断性和筛查性乳腺钼靶检查的数量均有所下降。为了降低乳腺癌死亡率，应提高乳腺钼靶筛查计划的参与率。
